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A B S T R A C T
Administration of omeprazole by ventriculo-cisternal perfusion or intravenously has been shown
to decrease cerebrospinal ﬂuid (CSF) production in dogs and rabbits. Oral omeprazole has consequently
been recommended to reduce CSF production in dogs with conditions in which clinical signs may be at-
tributable to an accumulation of CSF in the central nervous system (e.g. hydrocephalus, syringomyelia).
The albumin quotient (QAlb), the ratio between CSF and serum albumin concentration, has been pro-
posed as a reliable means to evaluate CSF production; decreasing CSF production should cause an increase
in QAlb.
The aims of this study were to assess the effect of oral administration of omeprazole on QAlb in dogs
and to compare two methods to assess CSF albumin concentration. Fifteen healthy Beagle dogs re-
ceived omeprazole (1.2 mg/kg/day) orally for 14 days; CSF and blood were obtained before and after
treatment. CSF albumin concentrations were evaluated by nephelometry and high-resolution protein elec-
trophoresis. Regardless of the method used for measuring albumin, QAlb did not change signiﬁcantly
following oral omeprazole administration, suggesting that CSF production in healthy dogs may not be
affected by chronic oral therapy with omeprazole.
© 2016 Elsevier Ltd. All rights reserved.
Introduction
Omeprazole is a substituted benzimidazole that inhibits the H+-
K+ ATPase pumps of gastric parietal cells and is used as an effective
anti-ulcer therapy in people and companion animals worldwide
(Hersey and Sachs, 1995). Two experimental studies have demon-
strated that omeprazole can signiﬁcantly decrease cerebrospinal ﬂuid
(CSF) production (by 26–50%) following ventriculocisternal (VC) or
intravenous (IV) administration indogs and rabbits (Lindvall-Axelsson
et al., 1992; Javaheri et al., 1997). However, themechanismbywhich
omeprazole affectsCSFproductionwasnot elucidated in these studies.
Moreover, despite the fact that both studies only focused on the im-
mediate effect of IV or VC administration of omeprazole on CSF
production, oral administration (0.5–1.5mg/kg/day) is currently rec-
ommended for the long-term management of dogs with
hydrocephalus or syringomyelia (Rusbridge et al., 2006; Thomas,
2010; Plessas et al., 2012).
Hydrocephalus and syringomyelia are two conditions in which
a disturbance in CSF ﬂowmay provoke clinical signs in affected dogs.
Hydrocephalus is a multi-factorial disease involving distension of
the ventricular system with an increased volume of CSF. Obstruc-
tive hydrocephalus, the most common form, occurs secondary to
the inadequate passage of CSF from its site of production to its ab-
sorption site (DeLahunta and Glass, 2009; Rekate, 2009; Thomas,
2010). A developmental form of obstructive hydrocephalus is ob-
served in toyandbrachycephalic breedsalthough thepathophysiology
is not completely understood. The most common causes identiﬁed
are stenosis of themesencephalic aqueduct ormalformations of the
arachnoid villi (DeLahunta and Glass, 2009; Thomas, 2010). Neo-
plasia or inﬂammatory disease may also interfere with CSF ﬂow
causing acquired hydrocephalus.
Syringomyelia is a complex disease in which a reduced cross-
sectional area of the subarachnoid space contributes to altered CSF
dynamics leading to the formation of ﬂuid-cavitation in the spinal
cord. In dogs, syringomyelia may result from congenital cervical mal-
formations or subarachnoid diverticula. It may also occur secondary
to acquired disorders such as intervertebral disc disease or intra-
cranial neoplasia. The ﬂuid accumulation in the spinal cord has been
associatedwith pain or dysaesthesia (Rusbridge et al., 2007; Hu et al.,
2012; Driver et al., 2013). In both conditions, the principal goals of
medical management are to decrease CSF production, reduce CSF
accumulation in the ventricular system or spinal cord, and de-
crease CSF turbulence (Rusbridge and Jeffery, 2008; Thomas, 2010;
Driver et al., 2013).
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The VC perfusion technique is a well-establishedmethod to assess
CSF production rate. However, because the technique is invasive, it
is only applicable in experimental studies (Pappenheimer et al., 1961;
Lindvall-Axelsson et al., 1992; Javaheri et al., 1997) and an alter-
native method is required for clinical research on this topic. The
albumin quotient (QAlb) is the ratio between CSF and serum albumin
concentrations (Olsson and Pettersson, 1976; Reiber, 1994) and is
considered to be a reliable indicator of CSF ﬂow rate in humanmed-
icine (Reiber et al., 1993; Reiber, 1994, 2003). Any decrease in CSF
production should theoretically be accompanied by an increase in
QAlb (Reiber, 2003).
The aim of the present studywas to determine QAlb values before
and after oral administration of omeprazole in healthy dogs. We
hypothesised that QAlb (a surrogatemarker of CSF production) would
increase following omeprazole administration if oral omeprazole
effectively decreases CSF production. Several parameters other than
QAlb were measured on blood and CSF samples to investigate po-
tential mechanisms by which omeprazole would change CSF ﬂow.
A second goal was to look at the correlation between high-




The study was conducted with approval from the Ethical Committee for Exper-
imental Animals of the University of Liège (Record Number: 1370). All experiments
were performed under general anaesthesia and animal welfare was safeguarded
throughout the study. Fifteen experimental Beagle dogs, eight entire females and
seven entire males aged 6–13 years (mean 7.9 ± 2.4 years old) and weighing 14.2–
22.1 kg (mean 17.3 ± 2.6 kg) were used. All dogs were clinically healthy at physical
examination.
Experimental design
Blood and CSF sampling were performed in all dogs before and after 14 days of
oral omeprazole administration. In each dog, omeprazole (Omeprazole Mylan 10mg)
was administered orally at a dose of 1–1.40 mg/kg once daily (mean 1.20 ± 0.16 mg/
kg once daily). Dogs were clinically examined every day throughout the study period.
CSF albumin concentrations were evaluated by nephelometry and high-
resolution protein electrophoresis on paired CSF and serum samples, according to
guidelines from the International Consensus Group for CSF Analysis (Reiber et al.,
2003). CSF was checked for blood contamination or subclinical signs of inﬂamma-
tion by performing erythrocyte and leukocyte counts. Serum and CSF electrolyte,
total protein, glucose and lactate concentrations, as well as pH and plasma osmo-
lality were also determined.
Samples
Blood and CSF sampling were performed under general anaesthesia, maintained
with isoﬂurane (Isovet, Piramal Healthcare UK: 1.5%; oxygen at 0.8 L/min), after IV pre-
medication with methadone (Comfortan Eurovet; 0.4 mg/kg) and induction with IV
propofol (Diprivan AstraZeneca; 5 mg/kg bolus). During the procedure, oxygen sat-
uration wasmaintained over 96% and end tidal CO2 between 35 and 45mmHg. Rectal
temperature was measured to allow for correction of the measured pH.
From each dog, 2.2–2.5 mL of CSF was collected from the cerebellomedullary
cistern and placed into two 1.8 mL microcentrifuge tubes (Cryotubes). Blood was
sampled via jugular venepuncture immediately after obtaining the CSF sample. One
sample of blood and CSF was immediately assayed for erythrocyte and leukocyte
count and pH, lactate, glucose, total protein and electrolytemeasurements. The second
CSF tube was cooled (at 4 °C) for 24 h prior to nephelometric albumin measure-
ment. An aliquot of the remainder of the CSF and a serum sample were frozen (−20 °C
for 1 month) for high-resolution protein electrophoresis.
Analyses
CSF and venous blood pH were measured using a pH meter (Mettler Toledo
MP225) directly after collection. Each value was corrected with the Rosenthal factor
to allow for the difference between the temperature of the patient and that of the
measuring device:
Blood pHt Blood pHt1 2 0 0147 1 2= − −( ). t t
where t1 represents the rectal temperature of the dog, t2 the temperature of the
meter’s electrode (37 °C), blood pHt2 the pH reading by the electrode at 37 °C and
blood pHt1 the pH of the dog’s blood.
Osmolality was measured by freezing point depression (Osmo station OM-
6050 Menarini). Serum albumin and total protein concentrations were measured
using a colorimetric reaction with bromocresol green technique (Response 920,
Diasys). Red and white blood cells in CSF were counted using an automated analyser
(Cell-Dynn 3700). CSF total protein concentrations were measured by a colorimet-
ric reaction with pyrogallol red (Cobas Mira, Roche) (Behr et al., 2003).
High-resolution agarose gel electrophoresis was performed on paired CSF and
serum samples, after thawing, using a commercially available agarose gel (Hydragel
protein K20, Dyasis on Cobas mirror). A concentration step was performed on CSF
samples using a membrane microconcentrator technique (Vivaspin 500 VS0101, Sar-
torius). Paired CSF and serum samples were analysed during the same analytical run
and results were read by a semiautomatic system. The albumin concentrations in
serum and CSF were calculated by multiplying the total protein concentration of the
sample by the percentage value of the albumin from high-resolution protein
electrophoresis.
CSF albumin concentration was also determined by nephelometry, as previ-
ously described (Fink et al., 1989). A calibration of the human nephelometric assay
(BNII system, Kit N AS ALB, Siemens Healthcare) was deemed necessary because the
monoclonal antibody against human albumin used in the assay shared only a partial
cross-reactivity with canine albumin (Gentilini et al., 2005; Murgier et al., 2009). A
calibration curve was constructed by diluting a solution of puriﬁed canine albumin
(Canine Albumin Protein ab119814, Abcam) to concentrations varying between 1.6
and 100 mg/dL using 0.9% saline. Linearity was determined by comparing mea-
sured albumin concentrationswith those expected. Eachmeasurementwas performed
in duplicate. A standard curve with four points of calibration was obtained and dem-
onstrated excellent linearity in the range of 12.5–100mg/dL (Fig. 1). Dilutions beyond
12.5 mg/dL were below the threshold of detection of the assay.
QAlb was calculated as the ratio between CSF and serum albumin concentrations:
QAlb CSF Albumin g L Serum Albumin g L= [ ]( ) [ ]( )
Two values of QAlb were determined: the ﬁrst (QAlb1) was calculated from con-
centrations of CSF and serum albumin as determined by high-resolution protein
electrophoresis, and the second (QAlb2) using the concentration of CSF albumin de-
termined by the nephelometric assay and the concentration of serum albumin
determined with the bromocresol green technique.
Statistical analyses
A statistical analysis program (Sigmastat 3.5 Software) was used for calcula-
tions. Continuous data were analysed for normality using a Kolmogorov–Smirnov
test. All data were expressed as means ± SD. A paired t test was used to compare
results before and after treatment for parametric data. If data assumed a non-
normal distribution, the Wilcoxon Signed Rank test was used. A Pearson product
moment correlation was performed to compare the results obtained with the two
techniques (high-resolution protein electrophoresis and nephelometry assay) used
for the determination of albumin concentration.
To investigate the effect of age on QAlb, the dogs were separated into three groups
according to age. The ﬁrst group was composed of eight dogs of 6 years of age; the
second group was composed of three dogs that were 8.5 years old and the last group
included four older dogs (two 10.5-year-old dogs, one 11-year-old dog and one 13-
year-old dog).
A Kruskal–Wallis test was used to compare QAlb according to age. Results were
considered to be statistically signiﬁcant at a P value <0.05.
Results
CSF albumin concentration and QAlb
All electrophoresis proﬁles were considered interpretable with
a clear cut-off allowing determination of albumin concentration. Each
dog presented a type 1 protein electrophoresis proﬁle consistent
with those previously described in healthy dogs (Behr et al., 2006)
(Fig. 2).
There was a strong correlation between HRE and nephelom-
etry in determining CSF albumin concentration (correlation
coeﬃcient = 0.86, P < 0.0001) (Fig. 3). Compared with the nephelo-
metric assay, high-resolution protein electrophoresis consistently
underestimated CSF albumin concentrations.
There was no signiﬁcant difference in QAlb before and after
omeprazole administration regardless of the method used to cal-
culate QAlb (Table 2). When dogs were classiﬁed into three groups
according to their age, we observed an increase in QAlb with
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increasing age but the difference between groups was not statisti-
cally signiﬁcant (Fig. 4).
Changes in CSF and blood composition
No macroscopic blood contamination was observed in any CSF
sample. The number of erythrocytes in the CSF varied between 0 and
7000/μLwith no signiﬁcant difference betweenmedian red blood cell
counts before and after omeprazole administration. CSF pH, white
blood cell count, lactate, glucose and total protein concentrationswere
within normal limits in each dog and did not show signiﬁcant changes
after omeprazole administration. A minimal yet statistically signif-
icant increase in CSFNa+ concentrationwas observed after omeprazole
administration (CSF-Na+ pre-omeprazole = 144.3 ± 1.9 mmol/L; CSF-
Na+ post-omeprazole = 145.9 ± 1.1 mmol/L; t = −2.976; P = 0.010)
(Table 1).
Blood venous pH was slightly but statistically signiﬁcantly in-
creased after omeprazole administration (pre-omeprazole =7.43 ±0.05;
post-omeprazole = 7.50 ± 0.04; t = −4.111; P = 0.001). Serum electro-
lyte concentrations did not differ signiﬁcantly between day 0 and day
14 except for a mild decrease in serum Cl− concentration after
omeprazole administration (pre-omeprazole = 105.3 ± 1.7 mmol/L;
post-omeprazole = 103.3 ± 1.2mmol/L; Z = −2.866; P = 0.003). No other
variable was signiﬁcantly different following omeprazole adminis-
tration (Table 2).
Discussion
The present study is the ﬁrst to report the effect of omeprazole
on CSF production in dogs by using QAlb as a surrogate marker of
CSF production and we found no change in QAlb after 14 days of
oral omeprazole administration. It has been previously estab-
lished in human medicine that any decrease in CSF production will
cause an increase in QAlb in both physiological and pathological con-
ditions (Reiber, 1994, 2003; Reiber and Peter, 2001).
Albumin in CSF originates from blood only and reaches CSF by
numerous pathways at the level of the ventricles (i.e. at the level
of the choroid plexus, the ventricular surface and the
circumventricular organs), the cisterns or the lumbar and cortical
subarachnoid space (Reiber, 2003). Blood-derived protein dynam-
ics in CSF is deﬁned by the molecular ﬂux/CSF ﬂow theory in which
proteins diffuse passively from blood into CSF according to a con-
trolledmolecular size-dependent process (Felgenhauer, 1974; Reiber,
2003). Any increase in blood proteins is accompanied by an in-
crease in CSF proteins. Thus, QAlb is independent of blood changes
and is a relevant predictor of CSF ﬂow rate (Reiber, 1994, 2003).
Fig. 1. Canine calibration curve obtained for the automated nephelometric assay. The calibration curve was constructed by diluting a solution of puriﬁed canine albumin
(expected albumin concentrations).
Fig. 2. CSF and serum protein electrophoretic proﬁles in one healthy dog. Similar proﬁles were observed in all dogs and were all of type 1 (no globulin peak observed in
either CSF or serum). No proﬁle was considered non-interpretable (type 4).
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Without CSF ﬂow, proteins would diffuse from blood into CSF until
reaching equilibrium, as has been observed after death (Reiber, 2003).
Therefore, a decrease in CSF production is accompanied by an in-
crease in CSF protein concentrations (Reiber, 2003). The absence of
any change in QAlb after 2 weeks oral administration of omeprazole
could be interpreted as an absence of a sustained effect of
omeprazole on CSF production. The absence of an effect of oral ad-
ministration of omeprazole on QAlb could perhaps also be due to
low study power (type II error), although power calculations based
on previous data suggested we recruited a suﬃcient number of dogs.
The application of QAlbmeasurements in an experimental setting
enabled us to evaluate the effect of omeprazole on CSF production
without the need for invasive or CSF volumetric measurement. CSF
volumetric techniques using CT or MRI have been reported in dogs
(Daniel et al., 1995; Vite et al., 1997). However, to the best of our
knowledge, a link between CSF production and ventricular volume
has not been established in dogs. For this reason, imaging tech-
niques were not pursued in this study.
The absence of an effect of omeprazole on CSF production con-
trasts with previous studies in which omeprazole decreased short-
term CSF production in an experimental design. Lindvall-Axelsson
et al. (1992) were the ﬁrst to assess the effect of omeprazole on CSF
production. They showed that omeprazole caused a dose-related
reduction in CSF production in rabbits and they established an ap-
proximate minimum dose of 10−8mol/L when it was used VC. They
also demonstrated that an IV dose (0.2 mg/kg) of omeprazole de-
creased CSF production by 25% in rabbits. Javaheri et al. (1997)
performed a similar study in dogs. They showed a signiﬁcant re-
duction (~26%) in CSF production after adding 10−5 mol/L of
omeprazole to anaesthetised dogs by VC perfusion. An insuﬃcient
CNS concentration of omeprazole following oral administrationmight
have accounted for the lack of change in QAlb: the absence of mea-
surement of CSF omeprazole concentrations is a limitation of our
study.
Fig. 3. Correlation between CSF albumin concentration measurements obtained by nephelometry and by high-resolution electrophoresis (HRE). There was a strong corre-
lation between HRE and nephelometry to determine CSF albumin concentration (correlation coeﬃcient = 0.86, P < 0.0001).
Fig. 4. Scatterplot showing the albumin quotient (QAlb) for different age-grouped
healthy Beagle dogs. Dogs were separated into three groups according to age (eight
dogs of 6 years of age; three dogs of 8–9 years old and four dogs older than 10 years).
The cross (+) represents themean value and the horizontal line represents themedian.
There was an increase but not statistically signiﬁcant of QAlb with age in dogs
(P = 0.215), suggesting a decrease in canine CSF production with age.
Table 1
Cerebrospinal ﬂuid (CSF) values before (day 0) and after (day 14) oral administra-
tion of omeprazole (expressed as means ± standard deviation) in 15 healthy dogs.
A paired t test was performed for parametric data whereas a Wilcoxon Signed Rank
test was performed for non-parametric data (*). Only a slight increase in CSF sodium
concentration and slight decrease in albumin concentration determined by neph-
elometry after omeprazole administration were found to be statistically signiﬁcant
(bold).
Day 0 Day 14 P
pH 7.40 ± 0.03 7.41 ± 0.03 0.546
Cl− (mmol/L) 131.1 ± 3.6 129.8 ± 5.1 0.445
Na+ (mmol/L) 144.3 ± 1.9 145.9 ± 1.1 0.01
K+ (mmol/L) 2.83 ± 0.08 2.87 ± 0.05 0.109*
Ca2+ (mmol/L) 1.27 ± 0.07 1.31 ± 0.08 0.123
WBC count (cells/μL) 2.47 ± 1.85 2.20 ± 1.57 0.662
Lactate (mmol/L) 1.90 ± 0.20 1.81 ± 0.13 0.252*
Glucose (mmol/L) 4.19 ± 0.29 4.16 ± 0.17 0.654
Total proteins (g/L) 0.184 ± 0.087 0.167 ± 0.079 0.151*
Albumin (g/L) determined by HRE 0.094 ± 0.043 0.089 ± 0.045 0.368
Albumin (g/L) determined by
nephelometry
0.154 ± 0.059 0.147 ± 0.060 0.005
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In the present study only the effect of prolonged exposure to
omeprazole (14 days) was evaluated. Previous experiments have not
investigated the effects of omeprazole beyond several hours. De-
velopment of drug tolerance is a potential explanation for the lack
of change in QAlb after 2 weeks administration. Other drugs have
shown opposing effects when given acutely versus chronically. Acute
administration of ethanol reduced CSF production by about 40%
whereas alcoholic humans present enlarged cerebral ventricles (po-
tentially consistent with an increase in CSF production due to chronic
ethanol exposure) (Javaheri and Corbett, 1998). A similar effect on
CSF production has been observed with caffeine (Han et al., 2009;
Wostyn et al., 2011). This ‘effect inversion’ of caffeine may be sec-
ondary to the modulation of the expression of Na+-K+-ATPase in the
choroid plexuses by adenosine receptors (Han et al., 2009).
Puscas et al. (1999) demonstrated that omeprazole has the ability
to inhibit carbonic anhydrases I, II and IV. Based on this hypothe-
sis, Balakrishnan et al. (2001) studied the effect of omeprazole as
an anticonvulsive agent in rats and demonstrated that omeprazole
was a potentially effective antiepileptic drug that may act through
the inhibition of brain carbonic anhydrase. However, rats devel-
oped a rapid tolerance and were refractory to repeated
administration of omeprazole. It is possible that omeprazole de-
creases CSF production in acute conditions via inhibition of carbonic
anhydrase but that tolerance may develop with chronic
administration.
Several factors can interfere with CSF production and therefore
might have masked the effects of omeprazole in our study. To avoid
this, our experiment was carefully controlled: drugs used for an-
aesthesia were chosen because they were known not to interfere
with CSF production (Artru, 1983, 1984, 1993) and experimental
conditions were identical on day 0 and day 14.
Increased QAlb has been found in elderly people and is thought
to be due to reduced CSF production (Reiber, 1994, 2003; Silverberg
et al., 2003). The ﬁndings of an increase in QAlb with age in this
study suggest the presence of the same phenomenon in dogs but
further investigations with larger groups of dogs are needed to
conﬁrm this observation as a statistically signiﬁcant relationship was
not established.
A signiﬁcant decrease (P = 0.005) in CSF albumin concentration
(from 0.154 g/L to 0.147 g/L) was identiﬁed by nephelometry (but
there was no signiﬁcant difference found using high-resolution
protein electrophoresis). The absence of any concurrent change in
QAlb indicates that the difference in CSF albumin most likely re-
ﬂects variations in serum albumin levels. This highlights the
importance of using the QAlb ratio as the appropriate surrogate
marker rather than CSF albumin concentration alone.
Paired high-resolution protein electrophoresis is recommended
by the International Consensus Group for CSF Analysis (Reiber et al.,
2003). Electrophoresis proﬁles with low albumin concentrations are
frequently non-interpretable (Behr et al., 2006). Thanks to the
microconcentration step we used, all electrophoresis proﬁles were
interpretable even for albumin concentrations <20 mg/dL. High-
resolution protein electrophoresis was shown to be a good method
to estimate canine CSF albumin concentrations and represented an
easy and readily available method.
CSF albumin values determined by high-resolution protein elec-
trophoresis were lower than CSF values determined by nephelometry.
In this study, CSF total protein concentration was measured by a
colorimetric reaction with pyrogallol red. Although this technique
is considered to have the greatest speciﬁcity (Marshall andWilliams,
2000; Behr et al., 2003) it can underestimate CSF total protein in
dogs because of its 20% lower aﬃnity for globulin compared to
albumin (Behr et al., 2003). This discrepancy could contribute to an
underestimate in albumin values calculated by high-resolution
protein electrophoresis. The loss of a small quantity of low molec-
ular weight proteins during the microconcentration step could also
contribute to the lower CSF albumin found by high-resolution protein
electrophoresis. Further studies are required to determine the origin
of the bias observed.
The mild increase in blood pH and decrease in blood Cl− ob-
served after omeprazole administration could be due to omeprazole-
mediated inhibition of gastric acid and chloride secretion (Aichbichler
et al., 1997). To the authors’ knowledge, very little data concern-
ing the effects of omeprazole on blood pH and Cl− are available and
further investigations are indicated to assess the clinical signiﬁ-
cance of these ﬁndings.
We also found a signiﬁcant (although mild) increase in CSF Na+
concentration after omeprazole administration. This ﬁnding is op-
posite to that expected in the context of a decrease in CSF production.
Membrane transport mechanisms in the choroid plexus are similar
to those in the renal tubule; CSF production depends on the active
transport of Na+ into the ventricles (Johanson et al., 2008). A de-
crease in uptake of Na+ into CSF resulting in a reduction in CSF Na+
concentration and a reduction of CSF production was demon-
strated in dogs and rats treated with furosemide (Buhrley and Reed,
1972; Johnson et al., 1984). The importance of the minor CSF Na+
concentration change in our study is unknown butwould not support
a reduction in CSF production.
Our study has several additional limitations. High-resolution
protein electrophoresis was performed on samples that had been
frozen whereas nephelometry was performed on cooled samples.
However, as albumin has been demonstrated to be stable in frozen
urine (−20 °C) for at least 24 months (Tencer et al., 1997), it is un-
likely that the 1 month storage of CSF and plasma at −20 °C had a
signiﬁcant effect on albumin concentrations. It is also important to
note that the study was performed on healthy dogs and it is pos-
sible that dogs with hydrocephalus or syringomyelia may respond
differently. Further studies are required to assess the effects of
omeprazole on dogs suffering from hydrocephalus or syringomyelia.
Conclusions
The lack of change in QAlb in the present study suggests that
CSF production may not be affected following chronic oral therapy
Table 2
Blood values before (day 0) and after (day 14) oral administration of omeprazole
(expressed as means ± standard deviation) in 15 dogs. A paired t test was per-
formed for parametric data whereas a Wilcoxon Signed Rank test was performed
for non-parametric data (*). A signiﬁcant mild increase in blood pH, a slight de-
crease in serum Cl− concentrations and a slight decrease in albumin concentrations
were observed after omeprazole administration (bold). QAlb1 was calculated from
concentrations of CSF and serum albumin as determined by HRE, and QAlb2 was
calculated using the concentration of CSF albumin determined by the nephelomet-
ric assay and the concentration of serum albumin determined with the bromocresol
green technique. QAlb did not change signiﬁcantly after oral administration of
omeprazole for 14 days.
Day 0 Day 14 P
Blood venous pH 7.44 ± 0.05 7.50 ± 0.04 0.001
Cl− (mmol/L) 105.3 ± 1.7 103.3 ± 1.2 0.003*
Na+ (mmol/L) 144.9 ± 2.1 145.7 ± 2.0 0.217
K+ (mmol/L) 3.82 ± 0.39 3.85 ± 0.20 0.658
Ca2+ (mmol/L) 2.52 ± 0.09 2.54 ± 0.12 0.600
Osmolality (mOsm/kg) 300.00 ± 3.40 300.73 ± 2.15 0.413
Haematocrit (%) 41 ± 5 42 ± 4 0.361
RBC count (1012 cells/μL) 5.79 ± 0.67 5.89 ± 0.54 0.122
WBC count (109 cells/μL) 7.34 ± 1.45 7.23 ± 1.07 0.791
Lactate (mmol/L) 1.23 ± 0.35 1.35 ± 0.35 0.181
Glucose (mmol/L) 5.64 ± 0.48 5.70 ± 0.40 0.518
Total proteins (g/L) 60.33 ± 3.81 59.73 ± 4.08 0.346
Albumin (g/L) 31.33 ± 2.43 29.41 ± 2.37 <0.001
QAlb1 (×10−3) 2.69 ± 1.34 2.73 ± 1.45 0.966*
QAlb2 (×10−3) 4.91 ± 1.90 4.99 ± 2.20 0.525
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with omeprazole in healthy dogs. Additional work is needed to assess
the acute and chronic impact of omeprazole on CSF production in
neurological patients suffering from conditions relating to CSF
disturbance.
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